CSPC Pharmaceutical Group Limited - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
CSPCY Over the counter 2840 www.cspc.com.hk

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group (SEHK:1093) Stock May Be 44% Undervalued On RSV Trial Start - Oct 28th, 2026 11:08 am
CSPC Pharmaceutical Group (SEHK:1093) Reports Encouraging SYS6002 Data, Is The Valuation Gap Still Open? - Oct 15th, 2026 1:10 pm
Big Pharma Is Pouring Billions Into China’s Biotechs - Sep 14th, 2026 1:59 am
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 - Feb 14th, 2026 5:58 am
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC - Feb 2nd, 2026 9:00 am
CSPC AstraZeneca Deal Recasts Role In Global Obesity And Diabetes Therapies - Feb 1st, 2026 8:08 am
AstraZeneca Agrees Up to $18.5 Billion Obesity Drug Deal in China - Jan 30th, 2026 5:52 am
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology - Jan 26th, 2026 6:58 pm
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China - Dec 30th, 2025 7:49 am
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration - Dec 29th, 2025 10:45 am
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC - Dec 19th, 2025 9:54 pm
How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story - Nov 7th, 2025 4:17 am